Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712705 | 0.78 | MAPT (0.42) | MAPTCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1712608 | 0.78 | MAPT (0.46) | MAPTCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1713071 | 0.76 | MAPT (0.43) | MAPTCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL16348106 | 0.74 | MAPT (0.42) | MAPTCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL2746473 | 0.74 | MAPT (0.42) | MAPTCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL2136594 | 0.72 | MAPT (0.40) | MAPTCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL12347996 | 0.72 | RIPK1 (0.49) | MAPTCNR1 | |
| SCHEMBL2026936 | 0.72 | ALDH1A1 (0.32) | — | |
| SCHEMBL8434418 | 0.71 | MAPT (0.43) | MAPTCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL11282691 | 0.71 | MAPT (0.43) | MAPTCHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080053835-A1 | Monomer Compound, Process for Producing the Same, Polymer Thereof, and Water-Based Curable Composition | KANSAI PAINT CO., LTD. (JP) | 2008-03-06 | — | — | US | disclosed |
| US-20080053835-A1 | Monomer Compound, Process for Producing the Same, Polymer Thereof, and Water-Based Curable Composition | KANSAI PAINT CO., LTD. (JP) | 2008-03-06 | — | — | US | disclosed |
| EP-1798218-A1 | MONOMER COMPOUND, PROCESS FOR PRODUCING THE SAME, POLYMER THEREOF, AND WATER-BASED CURABLE COMPOSITION | KANSAI PAINT CO., LTD. (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080053835-A1 | Monomer Compound, Process for Producing the Same, Polymer Thereof, and Water-Based Curable Composition | THEM6, PAM, WEE1 | MAPT 1497/4885CHRNB2 3308/4885CHRNB4 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.